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The deﬁning characteristic of recessive disorders is the absence of disease in heterozygous carriers of the mutant alleles. However, it has
been recognized that recessive carriers may differ from noncarriers in some phenotypes. Here, we studied ataxia telangiectasia (AT),
a classical recessive disorder caused bymutations in the ataxia telangiectasia mutated (ATM) gene.We compared the gene andmicroRNA
expression phenotypes of noncarriers, AT carriers who have one copy of the ATM mutations, and AT patients with two copies of ATM
mutations. We found that some phenotypes are more similar between noncarriers and AT carriers compared to AT patients, as expected
for a recessive disorder. However, for some expression phenotypes, AT carriers are more similar to the patients than to the noncarriers.
Analysis of one of these expression phenotypes, TNFSF4 level, allowed us to uncover a regulatory pathway where ATM regulates TNFSF4
expression throughMIRN125B. In AT carriers and AT patients, this pathway is disrupted. As a result, the level ofMIRN125B is lower and
the level of its target gene, TNFSF4, is higher than in noncarriers. A decreased level ofMIRN125B is associated with breast cancer, and an
elevated level of TNFSF4 is associated with atherosclerosis. Thus, our ﬁndings provide a mechanistic suggestion for the increased risk of
breast cancer and heart disease in AT carriers. By integrating molecular and computational analyses of gene and microRNA expression,
we show the complex consequences of a human gene mutation.Introduction
Autosomal-recessive disorders are diseases that are
expressed in individuals with two copies of the mutant al-
leles. Carriers who have one copy of a mutant allele do
nothavephenotypes that differ fromnoncarriers.However,
as early as the 1940s, there were suggestions that heterozy-
gous carriers of recessive mutations may have phenotypic
manifestations.1 More recently, population-based studies
have shown that carriers of autosomal-recessive disorders
such as cystic ﬁbrosis, Gaucher disease, and ataxia telangi-
ectasia (AT; MIM 208900) have increased risk of asthma,2
parkinsonism,3 and breast cancer,4,5 respectively. Although
there are not many patients with recessive disorders, there
are many carriers of recessive mutations in the population.
In the case of AT, the carrier frequency is ~1 in 100. There-
fore, if heterozygousmutations lead todistinct phenotypes,
then carriers of these mutations contribute signiﬁcantly to
overall phenotypicdiversity andprobably todisease suscep-
tibility. Patients with AT, which is caused by mutations
in the ataxia telangiectasia mutated (ATM, MIM 607585)
gene, have cerebellar ataxia, oculocutaneous telangiectases,
immune deﬁciency, and predisposition tomalignancy. The
parents of AT patients are obligate carriers and do not have
features onphysical exams thatdistinguish themfromnon-
carriers. However, as a group, they have an increased risk of
breast cancer and heart disease.4,6 Mice heterozygous for
ATMmutations also have an increased risk for cancer7 and
metabolic syndrome.8 Genetic studies have identiﬁed
ATMmutations as susceptibility alleles for breast cancer,4,9
and molecular effects of genetic variants and/or mutationsin theATM gene10–12 have also been studied.However, little
progress has been made in understanding the functional
consequences of heterozygous ATMmutations. To address
this, we have carried out a genome-scale analysis.
Advances in genomics allow large-scale study of gene-ex-
pression patterns. The result is a much improved under-
standing of how gene expression relates to cellular pheno-
types. Gene-expression studies have the advantage of
resolution and scale that is difﬁcult to match in clinical
studies. Recently, we and others have shown that expres-
sion levels of genes, like other quantitative phenotypes,
are heritable,13–15 and thus their regulation can be geneti-
cally dissected. These studies show that allelic forms of
gene-expression regulators lead to different expression
levels of their target genes.16,17 This offers an opportunity
to determine the effect of gene mutations on downstream
targets, pathways, and, ultimately, cellular phenotypes.
With this as a premise, we investigated the effect of het-
erozygous and homozygous ATM mutations on gene and
microRNA expression. The results did not show a simple re-
cessive pattern. Instead, we found that some genes and
pathways require only one copy of wild-type ATM for nor-
mal function, and therefore exhibit a recessive pattern.
Others require two copies of wild-type ATM and show a
dominant pattern. To better understand the unexpected
dominant gene-expression phenotypes, we further ana-
lyzed one of them, TNFSF4 (MIM 603594) level, and
showed that it is regulated byATM throughMIRN125B. Pre-
vious studies have shown that MIRN125B18 and TNFSF419
are associated with breast cancer and heart disease. Thus,
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on its target genes and suggest amechanism for the suscep-
tibility of AT carriers to breast cancer and heart disease.
Material and Methods
Tissue Culture and Radiation Treatment
Lymphoblastoid cell lines (Coriell Cell Repositories, Camden, NJ)
from eight controls (ATM þ/þ), eight obligate heterozygous
AT carriers (ATMþ/), and eight AT patients (ATM/) (Table S1
available online) were grown at a density of 5 3 105 cells/mL in
RPMI 1640 with 15% fetal bovine serum, 2 mM L-glutamine,
and 100 U/mL penicillin-streptomycin and irradiated at 5 Gy in
a 137Cs irradiator. Cells were harvested prior to radiation and at
4 and 24 hr after exposure to ionizing radiation (IR).
mRNA Expression Measurements and Analysis
Total RNA samples were extracted with the RNeasy Mini Kit
(QIAGEN, Valencia, CA) and were used for probe preparation
and hybridization onto Affymetrix Human Genome Focus Gene-
Chip arrays according to the manufacturer’s suggestions (Affyme-
trix, Santa Clara, CA). Signal intensities and expression calls were
calculated with the dCHIP program with the rank-invariant nor-
malization and the perfect match (PM) options.20
For further analysis, we selected for genes that (1) are expressed
in lymphoblastoid cells and (2) are expressed at different levels
among controls, carriers, and/or patients at baseline and in re-
sponse to IR. Expressed genes are those that are called ‘‘present’’
in 65 or more samples (out of 72), and differentially expressed
genes are those that showed > 1.5-fold difference relative to the
baseline ATMþ/þ samples.
Two-Way Analysis of Variance
To identify genes with recessive and dominant expression proﬁles,
we performed two-way analysis of variance; the two factors were
genotype and time point. Genes whose expression levels across
time points were signiﬁcantly different between ATMþ/þ and
ATM/ and also between ATMþ/ and ATM/, but were not sig-
niﬁcantly different between ATMþ/þ and ATMþ/, were considered
to have a ‘‘recessive’’ expression proﬁle. Genes whose expression
levels across time points were signiﬁcantly different between
ATMþ/þ and ATM/ and also between ATMþ/þ and ATMþ/ but
not signiﬁcantly different between ATMþ/ and ATM/ were con-
sidered to have a ‘‘dominant’’ expression proﬁle. A threshold of
p < 0.01 was used for the gene-expression analysis.
miRNA Expression Measurements
Cell lines from the same eight ATMþ/þ, eight ATMþ/, and eight
ATM/ individuals as above were used to measure miRNA expres-
sion levels. miRNA fractions were extracted from the cells with the
PureLink miRNA Isolation Kit (Invitrogen, Carlsbad, CA). miRNA
samples were pooled according to ATM genotype and post-IR
time point. The Applied Biosystems Early Access Taqman qRT-PCR
miRNA panel was used to quantify the level of mature miRNAs.21
Reverse transcription and real-time PCR reactions with 17 ng of
miRNAper reactionwere performed for 157humanmiRNAaccord-
ing to the manufacturer’s instructions (Applied Biosystems, Foster
City, CA). Each measurement was done in quadruplicate.
Analysis of miRNA Expression
Only miRNAs that showed measurable signals in all of samples
were considered for analysis. Normalization of miRNA expression
levels was performed by rank-invariant method. MIRN21 was244 The American Journal of Human Genetics 83, 243–253, Augustfound to be the least variable among the samples and is used for
normalization of other miRNAs. For each gene, four replicate mea-
surements were obtained for each sample. In order to avoid arbi-
trary or subjective deﬁnition of outliers, we identiﬁed and re-
moved one replicate value that was most deviant from the mean
of the replicates. Similar to mRNA analysis, we ﬁltered out miRNA
that showed < 1.5-fold difference when compared to the baseline
measurement in the control samples. Then, we carried out two-
way analysis of variance as above. A threshold of p < 0.001 was
used for the miRNA analysis.
Analysis of Potential mRNA-miRNA Interactions
To identify potential targets of miRNAs in human genes, we used
the Target-Combo program, which compiles prediction results
from PicTar, TargetScanS, and miRanda.
TNFSF4 ELISA Assay
TNFSF4 proteins levels were quantiﬁed with humanOX40 Ligand/
TNFSF4 Immunoassays (R&D Systems, Minneapolis, MN). Assay
was performed according to the manufacturer’s instructions.
Transfection Experiments
Lymphoblastoid cell lines were transfected with the Amaxa
Cell Line Nucleofector Kit V following the manufacturer’s
instructions (Amaxa Biosystems, Gaithersburg, MD). pMIR-
REPORT-TNFSF4-30UTRWTand pMIR-REPORT-TNFSF4-30UTRMUT
plasmids were generated by the cloning of double-stranded oligo-
nucleotides containing MIRN125B target sequence from TNFSF4
30UTR with and without a deletion of a seed sequence into
a pMIR-REPORTmiRNA Expression Reporter Vector (Ambion, Aus-
tin, TX). The following oligonucleotides were used for the cloning:
M125WT-FOR 50-AATGCACTAGTCCTCCCGCCCCCACCCCTCA
GGGATATTTAAAACTTATTTTATATAAGCTTAATGC-30, M125WT-
REV 50-GCATTAAGCTTATATAAAATAAGTTTTAAATATCCCTGAG
GGGTGGGGGCGGGAGGACTAGTGCATT-30, M125MUT-FOR 50-
AATGCACTAGTCCTCCCGCCCCCACCCACTTATTTTATATAAGC
TTAATGC-30, and M125MUT-REV 50-GCATTAAGCTTATATAAAAT
AAGTGGGTGGGGGCGGGAGGACTAGTGCATT-30. Prior to clon-
ing, appropriate oligonucleotides were annealed and digested
with HindIII and SpeI restriction endonucleases (New England
Biolabs, Ipswich, MA). pMIR-REPORT-TNFSF4-30UTR or pMIR-
REPORT-TNFSF4-30UTR MUT plasmids along with Renilla lucifer-
ase controlpRL-TKvector (Promega,Madison,WI)were transfected
into ATMþ/þ cells in triplicate. Cells were harvested 24 hr after
transfection and analyzed with Dual-Glo Luciferase Assay System
(Promega, Madison, WI). Expression of Renilla luciferase was used
as a normalization control.
For the overexpression assay, double-stranded human
MIRN125Bmimic and C. elegans MIRN67 control mimic (Dharma-
con, Lafayette, CO) were transfected into four ATM/ lympho-
blastoid cell lines. All experiments were done in duplicate. Cells
were harvested 48 hr after transfection. RNA was extracted with
RNeasy kit (QIAGEN, QIAGEN, Valencia, CA) and converted to
cDNA, and TNFSF4 expression was measured by real-time PCR.
Expression of beta-actin was used as a normalization control. The
following primers were used: TNFSF4-FOR 50-ATGAACCAACCCCT
GGAAGC-30, TNFSF4-REV 50-GTTTGGAGGCTGGGAAAGC-30,
ACTB-FOR 50-AAGATCATTGCTCCTCCTGAGC-30, and ACTB-REV
50-CATACTCCTGCTTGCTGATCCA-30.
Analysis of miRNA Promoter Sequences
Promoter sequences deﬁned as 1000 bp upstream of the transcrip-
tion start site were obtained from the UCSC Genome Browser.8, 2008
Then, we used MATCH program in TRANSFAC database (version
9.3) and the vertebrate matrices to identify transcription-factor
binding sites. Signiﬁcance of overrepresentation of binding site
between categories was evaluated with the Fisher’s Exact Test.
Quantitative Real-Time PCR and Chromatin
Immunoprecipitations
CDX2 expression was measured in eight ATMþ/þ, eight ATMþ/,
and eight ATM/ lymphoblastoid cell lines by quantitative PCR
with the following primers: CDX2-FOR 50-TCTCTTCCCTTCCCA
GACCA-30 and CDX2-REV 50-CACCCTGTGCATACACCAGC-30.
Expressionof beta-actinwas used as a normalization control. Chro-
matin immunoprecipitation (ChIP) was performedwith CDX2 an-
tibodies (BioGenex Laboratories, San Ramon, CA) according to the
protocol developed by Affymetrix. In brief, 3 3 107 cells were har-
vestedper sample andcrosslinkedwith formaldehyde at aﬁnal con-
centration of 1% for 20 min. The formaldehyde reaction was
quenched; the cells were washed and lyzed. Then, the samples
were sonicated to shear the DNA to 100–500 bp fragments with
a Branson Soniﬁer 450 (12 cycles, 30 s, 70% duty cycle, output 4).
Approximately 25 ug of CDX2 antibody was used for each immu-
noprecipitation reaction. Immunocomplexes were recovered with
protein A Sepharose CL-4B (GE Healthcare, Piscataway, NJ). Prod-
ucts from the immunoprecipitation reactions were analyzed by
quantitative real-time PCR with the following primer pairs:
MIRN125B2-FOR 50-GGGCCCACCTTACCAGTTGT-30 and
MIRN125B2-REV 50-AATTTTGCTTCCCATTACACTGC-30 (de-
signed to amplify a region in human MIRN125B2 promoter with
the putative CDX2 binding site as indicated by the MATCH pro-
gram in TRANSFAC) and MIRN125B2-UPST-FOR 50-AGCTCAG
GAAACTGGATCTTGG-30 and MIRN125B2-UPST-REV 50-
TCTTTGACCTTATGTGCCCCTT-30 (designed to amplify a region
upstream ofMIRN125B2 promoter). Input samples that were cross-
linked and fragmented but did not undergo immunoprecipitation
were used for normalization. Enrichment of CDX2 binding site in
theMIRN125B2promoterwas assessedbyqRT-PCRandnormalized
to the level in the preimmunoprecipitated input DNA. Two inde-
pendent cell lines were analyzed for each genotype.
Results
Gene-Expression Phenotypes in AT
ATM is known to play a role in cellular response to ionizing
radiation. We began by comparing the gene-expression
phenotypes of irradiated cells from individuals with zero,
one, or two mutated ATM alleles. We exposed lymphoblas-
toid cells from eight controls, eight obligate heterozygous
ATcarriers, and eight AT patients (Table S1 available online)
to 5 Gy of IR and collected cells at baseline and 4 and 24 hr
after exposure. Then, for each individual, RNAsampleswere
extracted and hybridized onto Affymetrix gene-expression
microarrays. This gave us data from 72 microarrays (8 sam-
ples/genotype 3 3 genotypes 3 3 time points).
Among the genes on the microarrays, there are 954
genes that showed at least a 1.5-fold difference in expres-
sion level compared to that of controls at baseline; we fo-
cused on these genes for subsequent analyses. We carried
out analysis of variance (ANOVA) to determine the effect
of ATM genotype on IR-induced gene-expression pheno-The Ametypes. Phenotypes are categorized as recessive when the
IR response patterns are similar between AT carriers and
noncarriers but signiﬁcantly different (p < 0.01 by
ANOVA) from AT patients (Figure 1A). Dominant pheno-
types are those where the IR-induced expressions are differ-
ent between AT carriers and noncarriers (p < 0.01 by
ANOVA) but the expression is similar between AT carriers
and AT patients (Figure 1B).
Because AT is a recessive disorder, we had expected to
ﬁnd gene-expression phenotypes that exhibit recessive
patterns. But instead, we found both recessive and domi-
nant expression phenotypes. At the signiﬁcance threshold
of p < 0.01 (ANOVA), we found 22 mRNAs that showed a
recessive pattern (Figure 1C) and 29 with a dominant pat-
tern (Figure 1D). Among the recessive phenotypes are ones
that play a role in DNA replication, such as MCM3 (MIM
602693) and MCM5 (MIM 602696) (minichromosome
maintenance), and in regulation of apoptosis, such as
C12orf5 (also known as TIGAR, MIM 610775).22 The dom-
inant phenotypes include themismatch repair gene,MSH2
(MIM 609309), and genes involved in lipid metabolism,
FADS2 (fatty acid desaturase, MIM 606149) and FASN (fatty
acid synthase, MIM 600212).
Pathway analyses of the genes show that many of the re-
cessive gene-expression phenotypes belong to the ATM-
p53 pathway (Figure 1E) whereas the dominant gene-ex-
pression phenotypes belong to the ATM-AKT pathway
(Figure 1F). These ﬁndings suggest that even though the
expression level of the ATM gene is not signiﬁcantly differ-
ent (p > 0.4) between carriers and noncarriers, there are
functional differences. Transcriptional activation of some
p53-mediated pathways can be achieved with one wild-
type copy of ATM, but components of other pathways
such as the AKT pathway require two functional copies
of ATM.
MicroRNA Expression Phenotypes in AT
Since the discovery of miRNA in 1993,23 many studies
have shown that these short (~21–23 nucleotides) single-
stranded RNA molecules play a critical role in regulating
gene expression in different organisms from C. elegans to
humans (reviewed in 24,25). The role of miRNAs in develop-
ment and growth regulation are well documented (re-
viewed in 26). However, their role in disorders that are
caused by germline mutations is less well studied. We com-
pared the miRNA expression phenotypes to determine
whether they differ among individuals with different
ATM genotypes and whether they inﬂuence gene-expres-
sion phenotypes.
We extractedmiRNA from lymphoblastoid cells from the
same 24 individuals of three ATM genotypes described
above (eight controls, eight AT carriers, and eight AT pa-
tients). MiRNA was collected before irradiation and at 4
and 24 hr after IR, as in the gene-expression study. The cells
were then pooled by genotype and time point. miRNA ex-
pression was studied with a quantitative real-time PCR
(qRT-PCR) panel that allowed us to measure the expressionrican Journal of Human Genetics 83, 243–253, August 8, 2008 245
Figure 1. Gene-Expression Phenotypes of Noncarriers, AT Carriers, and AT Patients
(A and B) An example of a gene, CDKN1A, that shows recessive pattern of expression (A) and a gene, FBXO5, that shows dominant pattern
of expression (B) in response to radiation.
(C and D) Twenty-two gene-expression phenotypes that show a recessive pattern of expression (C) and 29 gene-expression phenotypes
that show a dominant pattern of expression (D).246 The American Journal of Human Genetics 83, 243–253, August 8, 2008
Figure 2. MicroRNA Phenotypes of Noncarriers, AT Carriers, and AT Patients
Fifteen miRNA expression phenotypes that show a recessive pattern of expression (A), and seven miRNA phenotypes that show a dominant
pattern of expression (B). Expression values were obtained with qRT-PCR and are presented as n-fold change relative to that of noncarriers
at baseline. Two-way ANOVA was performed (p< 0.001, see Material and Methods); eight individuals per genotype were analyzed. miRNAs
and their target genes that show recessive (C) and dominant (D) patterns of expression. The programs that predicted the miRNA and
target-gene relationship are shown (PT ¼ PicTar, TS ¼ TargetScan, and MR ¼ miRanda). Correlation coefficients for expression levels
between the miRNAs and their targets are also shown.levels of 157 miRNAs. Among them, there are 79 miRNAs
that are expressed in lymphoblastoid cell lines and whose
expression levels after irradiation differ by 1.5-fold or more
compared to expression level of controls at baseline (Table
S2). We carried out an ANOVA (similar to the gene-expres-
sion analysis) on these miRNA to compare the IR-induced
miRNA expression patterns among individuals with differ-
ent ATM genotypes. As with the gene-expression pheno-
types, we observed both recessive and dominant pheno-
types. There were 15 miRNAs with recessive patterns
where the IR-induced expression patterns were similar
between noncarriers and AT carriers but were signiﬁcantly
different (p < 0.001) from AT patients (Figure 2A). Among
these 15 miRNAs areMIRN181A2 andMIRN195, which are
known to play a role in tumorigenesis27 and regulation of
stress-induced cell growth.28 In addition, there were seven
miRNAs that exhibit dominant IR-induced patterns wherethe proﬁles were similar between carriers and AT patients
but were signiﬁcantly different (p < 0.001) from noncar-
riers (Figure 2B). Of these seven miRNAs, MIRN125B is of
particular interest because it has been shown to be dysregu-
lated in breast cancer tissue18 and AT carriers have in-
creased risk of breast cancer (MIM 111480).4,5,7 The results
were obtained in pooled samples, so we validated the ﬁnd-
ings forMIRN125B in individual samples (Figure S1). Previ-
ous work showed that MIRN125B regulates gene expres-
sion by deadenylation of its target genes, which leads to
rapid mRNA decay.29
mRNA-MicroRNA Pairs with the Same Mode
of Inheritance
Thus far, we have analyzed gene expression and miRNA
separately; next, we combined the two datasets to deter-
mine whether we can attribute the gene-expression(E and F) Expression values were obtained with gene-expression microarrays and are presented as n-fold change relative to that of non-
carriers at baseline. Two-way ANOVA was performed (p < 0.01, see Material and Methods); eight individuals per genotype were analyzed.
Pathways identified with the Ingenuity program show that genes with recessive pattern (in purple) belong to the TP53-ATM pathway (E)
and genes with dominant pattern (in light green) belong to the AKT-ATM pathway (F).
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phenotypes to the miRNAs that regulate their expression.
We used TargetCombo, a computer program that com-
piles results from several miRNA target computational
prediction programs such as miRanda,30 PicTar,31 and
TargetScans,32 to determine whether the gene-expression
phenotypes with recessive patterns are targets of the
miRNAs with recessive patterns, and similarly for the dom-
inant phenotypes. Figures 2C and 2D show the pairs of
miRNAs and their predicted target genes that exhibit reces-
sive and dominant patterns of expressions, respectively.
Some of the target genes were identiﬁed by two or more
prediction programs and therefore are more likely to be
‘‘true’’ target genes.
Because miRNAs are mostly negative regulators of gene
expression, we would expect a negative correlation be-
tween the expression levels of the miRNAs and their target
genes. To examine this, we calculated correlation coefﬁ-
cients between the expression levels of the miRNAs and
their potential targets (Figures 2C and 2D). In some cases,
we found the expected negative correlation in expression
levels of the miRNAs and their target genes. For example,
the correlation coefﬁcient betweenMIRN125B and TNFSF4
was 0.63. However, positive correlations were also found;
these could be due to indirect regulatory effects, upregula-
tion of target genes by miRNAs,33 or false-positive miRNA
target identiﬁcation.
MIRN125B Targets TNFSF4
Because the dominant expression phenotypes are unex-
pected, we followed up one of the ﬁndings by molecular
analysis. We selected MIRN125B and its potential target
TNFSF4 (also known as OX40L) for further study.
MIRN125B and TNFSF4 are of interest because they have
been implicated in breast cancer18 and heart disease19,34
(MIM 608446), the diseases that were found to be associ-
ated with AT heterozygosity.5,6,7,35
Our mRNA expression-proﬁling results showed that
mRNA level of TNFSF4 is signiﬁcantly (p < 0.005) higher
in ATcarriers and patients compared to controls at baseline
and after exposure to IR (Figure 1D). We conﬁrmed the mi-
croarray result by qRT-PCR (Figure S2). The protein expres-
sion of TNFSF4 as assessed by ELISA assay is also higher in
cells derived from AT carriers and patients (Figure 3A). Se-
quence analysis showed a binding site of MIRN125B in
the 30 end of TNFSF4. This putative binding site is highly
conserved in multiple species including mouse, dog, and
human (Figure 3B).
We carried out molecular analysis to determine whether
TNFSF4 is a target of MIRN125B. First, we examined the
functional legitimacy of the putative binding site of
MIRN125B in the 30 UTR of TNFSF4 by subcloning a geno-
mic sequence containing theMIRN125B binding sequence
shown in Figure 3B into ﬁreﬂy luciferase-reporter con-
structs. We also examined a mutant sequence where the
conserved sequence of MIRN125B was deleted. We trans-
fected the constructs with the wild-type and mutant se-
quences separately into lymphoblastoid cells from noncar-248 The American Journal of Human Genetics 83, 243–253, Augustriers (who have high endogenous MIRN125B, as shown in
Figure 2B). The construct with the wild-typeMIRN125B se-
quence resulted in a decrease in luciferase activity, whereas
the construct with the mutant sequence did not downre-
gulate the reporter (Figure 3C). Next, we examined the in-
teraction between MIRN125B and TNFSF4 by transfection
ofMIRN125B into cells from AT patients (who have low en-
dogenous MIRN125B levels, as shown in Figure 2B). After
transfection of synthetic mimics of MIRN125B, we mea-
sured the level of TNFSF4 in the transfected cells by qRT-
PCR. We observed a decrease in the expression level of
TNFSF4 levels, whereas no change in TNFSF4 level was ob-
served in the cells transfected with a miRNA speciﬁc to
C. elegans (Figure 3D). These ﬁndings support our conclu-
sion that TNFSF4 is a target of MIRN125B.
CDX2 Is a Transcriptional Repressor of MIRN125B
Our data show that miRNAs expression patterns are associ-
ated with the expression patterns of some gene-expression
phenotypes. To identify the factors that inﬂuence miRNA
expression, we used Match,36 a weight-matrix-based tool,
and TRANSFAC (version 9.3), a database of transcription-
factor binding sites, to search for transcription-factor bind-
ing sites in the promoters of the miRNAs that showed re-
cessive and dominant expression patterns. We found that
there is an enrichment of AP2 binding sites in the pro-
moters of recessive miRNA (p ¼ 0.01) and an enrichment
of CDX binding sites in the promoter regions of the dom-
inant miRNAs (p ¼ 0.04), including MIRN125B. Table 1
shows the miRNAs with binding sites for AP-2 or CDX in
their promoter regions.
To study the expression of CDX transcription factors, we
used qRT-PCR to measure the expression level of CDX1
(MIM 600746) and CDX2 (MIM 600297) in lymphoblas-
toid cells from noncarriers, ATcarriers, and AT patients. Re-
sults showed that the CDX1 level is similar in individuals
with different ATM genotypes (data not shown); however,
the CDX2 level is signiﬁcantly higher in AT carriers and AT
patients compared to noncarriers (Figure 4A).
To assess whether CDX2 is indeed a regulator of
MIRN125B, we carried out ChIP assays. In the ChIP assays,
we used an antibody speciﬁc for CDX2 to assess its binding
to the promoter of MIRN125B in cells from individuals
with the three different ATM genotypes. After immunopre-
cipitation, we recovered signiﬁcantly moreMIRN125B pro-
moter fragments from AT carriers and patients than from
noncarriers (Figure 4B). This observation is consistent
with the higher expression level of CDX2 in AT carriers
and patients than controls (Figure 4A). No enrichment
was seen in negative controls: in a genomic region up-
stream of MIRN125B promoter and when mock im-
munoprecipitations were carried out without antibody
(Figure S3).
Other studies have shown that CDX2 acts as a transcrip-
tional repressor.37,38 Therefore, we hypothesize that in-
creased CDX2 binding results in lower levels ofMIRN125B
in AT carriers and patients (Figure 2B). The relatively lower8, 2008
Figure 3. TNFSF4 Is a Target Gene of MIRN125B
(A) Protein level of TNFSF4 at baseline in AT carriers and patients as compared to noncarriers (n ¼ 3 of each genotype).
(B) The consensus binding sequence of MIRN125B located in the 30UTR of TNFSF4 is shown. The sequence is highly conserved among
species.
(C) Luciferase-reporter assays in cells from noncarriers with wild-type binding sequence of MIRN125B in the 30 UTR of TNFSF4 or mutant
sequence where conserved binding site of MIRN125B was deleted (n ¼ 3).
(D) TNFSF4 mRNA levels in AT cells transfected with C.elegans miRNA or MIRN125B (n ¼ 4).
Error bars represent standard error of the mean.level ofMIRN125B in turn results in less downregulation of
its target gene, TNFSF4 (Figures 3C and 3D), which is then
expressed at a higher level in AT carriers and patients
(Figure 1D).The AmATM Regulates TNFSF4 via CDX2
Previous studies have also shown that ATM negatively reg-
ulates the expression of CDX2 through the ERK39 and AP-1
pathways.40,41 On the basis of these and our results, weerican Journal of Human Genetics 83, 243–253, August 8, 2008 249
Table 1. Transcription-Factor Binding Sites in the Promoter Regions of miRNAs
Transcription Factors
Fraction of Recessive
miRNAs with Binding
Sites (%)a
Recessive miRNAs with
Binding Sites
Fraction of Dominant
miRNAs with Binding
Sites (%)a
Dominant miRNAs with
Binding Sites p Valuec
AP-2 58 MIRN96, MIRN181C,
MIRN182, MIRN183,
MIRN190, MIRN195,
MIRN199A2, MIRN199B,
MIRN200B, MIRN205,
MIRN320
10 MIRN199A2 0.01
CDX 21 MIRN16, MIRN20A,
MIRN181Ab
60 MIRN10A, MIRN99A,
MIRN100, MIRN125B2,
MIRN218b
0.04
Promoter region is defined as 1000 bp upstream of transcription start site.
a The 15 ‘‘recessive miRNAs’’ are encoded by 19 distinct genes; the seven ‘‘dominant miRNAs’’ are encoded by ten distinct genes. Some miRNAs are encoded
by nearly identical genes that are located in more than one genomic location.
b Encoded by two distinct genes that are nearly identical; both copies contain the transcription-factor binding site.
c Fisher’s exact test.propose the following interpretation (Figure 5). ATM regu-
lates transcription regulators such as CDX2, which in turn
regulates the expression of miRNAs including MIRN125B.
The miRNAs then inﬂuence the expression of target genes
such as TNFSF4.
Discussion
Traditionally, Mendelian disorders have been classiﬁed as
recessive or dominant. However, there is increasing recog-
nition that this simple classiﬁcation is not the ‘‘whole
story.’’ Here, we investigated the mechanism underlying
the ﬁnding that AT carriers and noncarriers have different
phenotypes. Population-based studies have shown that
even though AT is a recessive disorder, AT carriers have in-
creased risks of breast cancer and heart disease. Studies
have suggested that some ATM variants and/or mutations
act in a dominant-negative manner and therefore predis-
pose carriers to cancer.7,9,42 Our results provide an alterna-tive view: The samemutations have different effects on dif-
ferent pathways. Some pathways require two copies of
wild-type ATM, whereas other pathways require only one
wild-type copy of ATM. These gene pathways probably af-
fect clinical phenotypes. Thus, some clinical manifesta-
tions of ATMmutations are seen only in patients, whereas
others are observed in both carriers and patients. Our re-
sults illustrate the complexities of human gene mutations
and emphasize the importance of studying biological
processes as ‘‘networks’’ rather than as distinct gene-gene
interactions.
By incorporating our ﬁndings and those in published
studies on MIRN125B and TNFSF4, we suggest a mecha-
nism for the increased risk of breast cancer4,5 and cardio-
vascular disease6,35,43 in AT carriers. Previous studies have
shown that breast cancer cells have lower expression levels
ofMIRN125B.18We found that ATcarriers have lower levels
ofMIRN125B; this may account for their risk of breast can-
cer. We also show that TNFSF4 is a target ofMIRN125B. The
lower MIRN125B levels in AT carriers resulted in higherFigure 4. CDX2 Regulates the Expression of MIRN125B
(A) The expression level of CDX2 by qRT-PCR in AT carriers and patients and compared to noncarriers (n ¼ 8 of each genotype).
(B) Results of ChIP assay with CDX2 antibodies showing the binding of CDX2 to promoter of MIRN125B in AT carriers and patients as
compared to noncarriers (n ¼ 2 of each genotype).
Error bars represent standard error of the mean.
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levels of its target gene, TNFSF4. Previous positional-clon-
ing results showed that TNFSF4 is a susceptibility gene
for cardiovascular disease19 and demonstrated that mice
overexpressing Tnfsf4 had larger atherosclerotic lesions
than control mice.19 This ﬁnding was supported by a study
that showed that disruption of the Tnfsf4 pathway attenu-
ates atherosclerosis in LDLR-deﬁcient mice.34 In addition,
it has been shown that augmentation of ATM activity by
chloroquine or related agents improves symptoms of met-
abolic syndrome.8 Our results provide molecular evidence
for how ATM inﬂuences TNFSF4 expression: The disrup-
tion of normal ATM function in ATcarriers leads to overex-
pression of TNFSF4, which then contributes to elevated
risk of heart disease. Like all complex traits, breast cancer
and atherosclerosis susceptibilities are inﬂuenced by
many genetic variants. Our results suggest one of the
mechanisms for increased susceptibility for these diseases
in AT carriers.
Although the levels of MIRN125B and TNFSF4 in pa-
tients are similar to those in carriers, breast cancer and car-
diovascular diseases are not commonly seen in patients.
This is probably because many AT patients succumb to leu-
kemia or lymphoma in their twenties. Breast cancer and
cardiac diseases usually develop later in life.
Our ﬁndings have implications beyond AT. Previously, it
was estimated that each individual is heterozygous for at
least several deleterious mutations.44 Also, a recent report
by Bustamente and colleagues shows that an individual
on averagemay be heterozygous for ~425 nonsynonymous
potentially deleterious SNPs.45 Thus, heterozygous reces-
sive mutations probably have an important inﬂuence on
human phenotypic diversity and susceptibility to complex
Figure 5. Proposed Model of the Regulation of Expression
Phenotypes
ATM regulates transcription factors, such as CDX2, which regulate
expression of microRNAs that in turn regulate expression level of
genes, including TNFSF4.The Amephenotypes and diseases. A systems approach that com-
bines genetics with genomic and molecular tools allowed
us to uncover the network of transcriptional regulators
that inﬂuences phenotypes in AT carriers. This work can
be extended to study other gene mutations in order to
quantify the contribution of heterozygous recessive muta-
tions to phenotypic variation.
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